- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2017
- Public Summary Document (PSD) March 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2017 PBAC Meeting - Word
Adalimumab – March 2017
Adalimumab: Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL pre-filled pen; Humira®
Last updated
14 July 2017